We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider
Read MoreHide Full Article
In the latest trading session, Bristol Myers Squibb (BMY - Free Report) closed at $59.71, marking a +1.07% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 1.01%. At the same time, the Dow added 0.83%, and the tech-heavy Nasdaq gained 1.22%.
The biopharmaceutical company's shares have seen a decrease of 2.73% over the last month, surpassing the Medical sector's loss of 5.53% and the S&P 500's loss of 2.86%.
The investment community will be paying close attention to the earnings performance of Bristol Myers Squibb in its upcoming release. On that day, Bristol Myers Squibb is projected to report earnings of $1.46 per share, which would represent a year-over-year decline of 18.89%. Simultaneously, our latest consensus estimate expects the revenue to be $10.86 billion, showing a 3.02% drop compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $6.26 per share and revenue of $47.02 billion, which would represent changes of +1.79% and -2.44%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Bristol Myers Squibb. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.7% increase. Currently, Bristol Myers Squibb is carrying a Zacks Rank of #3 (Hold).
In terms of valuation, Bristol Myers Squibb is presently being traded at a Forward P/E ratio of 9.44. This valuation marks a discount compared to its industry average Forward P/E of 18.91.
Meanwhile, BMY's PEG ratio is currently 0.17. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.52.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 143, putting it in the bottom 42% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Bristol Myers Squibb (BMY - Free Report) closed at $59.71, marking a +1.07% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 1.01%. At the same time, the Dow added 0.83%, and the tech-heavy Nasdaq gained 1.22%.
The biopharmaceutical company's shares have seen a decrease of 2.73% over the last month, surpassing the Medical sector's loss of 5.53% and the S&P 500's loss of 2.86%.
The investment community will be paying close attention to the earnings performance of Bristol Myers Squibb in its upcoming release. On that day, Bristol Myers Squibb is projected to report earnings of $1.46 per share, which would represent a year-over-year decline of 18.89%. Simultaneously, our latest consensus estimate expects the revenue to be $10.86 billion, showing a 3.02% drop compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $6.26 per share and revenue of $47.02 billion, which would represent changes of +1.79% and -2.44%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Bristol Myers Squibb. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.7% increase. Currently, Bristol Myers Squibb is carrying a Zacks Rank of #3 (Hold).
In terms of valuation, Bristol Myers Squibb is presently being traded at a Forward P/E ratio of 9.44. This valuation marks a discount compared to its industry average Forward P/E of 18.91.
Meanwhile, BMY's PEG ratio is currently 0.17. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.52.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 143, putting it in the bottom 42% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.